Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Kymera Therapeutics stock

Learn how to easily invest in Kymera Therapeutics stock.

Kymera Therapeutics Inc is a biotechnology business based in the US. Kymera Therapeutics shares (KYMR) are listed on the NASDAQ and all prices are listed in US Dollars. Kymera Therapeutics employs 143 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Kymera Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KYMR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Kymera Therapeutics stock price (NASDAQ: KYMR)

Use our graph to track the performance of KYMR stocks over time.

Kymera Therapeutics shares at a glance

Information last updated 2022-07-02.
Latest market close$21.10
52-week range$13.15 - $69.12
50-day moving average $19.54
200-day moving average $42.47
Wall St. target price$63.08
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.49

Buy Kymera Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Kymera Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kymera Therapeutics price performance over time

Historical closes compared with the close of $21.1 from 2022-07-01

1 week (2022-06-24) 4.82%
1 month (2022-06-02) 44.13%
3 months (2022-03-30) -49.17%
6 months (2022-01-03) -67.38%
1 year (2021-07-02) -62.61%
2 years (2020-06-29) N/A
3 years (2019-06-29) N/A
5 years (2017-06-29) N/A

Kymera Therapeutics financials

Revenue TTM $63.8 million
Gross profit TTM $-64,185,000
Return on assets TTM -15.12%
Return on equity TTM -35.18%
Profit margin -194.23%
Book value $8.31
Market capitalisation $1.1 billion

TTM: trailing 12 months

Kymera Therapeutics share dividends

We're not expecting Kymera Therapeutics to pay a dividend over the next 12 months.

Kymera Therapeutics overview

Kymera Therapeutics, Inc. , a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. .

Frequently asked questions

What percentage of Kymera Therapeutics is owned by insiders or institutions?
Currently 7.387% of Kymera Therapeutics shares are held by insiders and 92.476% by institutions.
How many people work for Kymera Therapeutics?
Latest data suggests 143 work at Kymera Therapeutics.
When does the fiscal year end for Kymera Therapeutics?
Kymera Therapeutics's fiscal year ends in December.
Where is Kymera Therapeutics based?
Kymera Therapeutics's address is: 200 Arsenal Yards Boulevard, Watertown, MA, United States, 02472
What is Kymera Therapeutics's ISIN number?
Kymera Therapeutics's international securities identification number is: US5015751044

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site